DUBLIN – Even if much of the focus of the inaugural Biopharma Ambition meeting here was, as the name suggests, on how Ireland can compete to win more investment from the global biopharma industry, scheduling Sir Andrew Dillon, CEO of England's National Institute for Health and Care Excellence (NICE), as the final speaker in the final plenary session, suggested a certain amount of realism on the part of the conference organizers. Read More
DUBLIN – A mere four months after its formation, German startup Iomx Therapeutics GmbH raised €40 million (US$44.6 million) in a series A round to develop antibody-based therapeutics against tumor-derived immune checkpoint targets. Read More
Preclinical work by researchers from Danish Orphazyme ApS has demonstrated that targeting heat-shock protein 70 (Hsp70) could alleviate a number of different lysosomal storage diseases, a group of several dozen rare to ultra-rare disorders united by mutations in proteins that lead to problems with cellular waste disposal. Read More
Newly formed Seelos Therapeutics Inc. is "pretty well positioned to raise money," Ligand Pharmaceuticals Inc. President Matthew Foehr told BioWorld Today, and that's what Seelos needs to do in the four-piece licensing deal with San Diego-based Ligand. Read More
Let's hear a round of applause for a milestone in U.S. drug development, and for dramatic effect pipe in a little background music from Jerry Lewis singing "Smile," the opening theme song from his annual Muscular Dystrophy Association Telethon. Read More
Sarepta Therapeutics Inc., of Cambridge, Mass., said it is offering to sell, subject to market and other conditions, up to $225 million of its common stock in a public offering and will grant underwriters a 30-day option to purchase up to an additional 15 percent of shares. Read More
Kadmon Holdings Inc., of New York, said the first patient was dosed in a 150-participant, double-blind, placebo-controlled phase II trial of KD025, the company's oral inhibitor of Rho-associated coiled-coil kinase 2, in moderate to severe chronic plaque psoriasis. Read More
